Plain-English translation of NCT04339062 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial tested , a medication that helps your immune system recognize and attack cancer cells, in people with advanced cutaneous squamous cell carcinoma who had previously received either a stem cell transplant or a kidney transplant. The trial investigated whether this treatment was safe and effective for this specific group of patients, since it had not been previously studied in transplant recipients.
While this medication was already approved by the FDA for advanced skin cancer in general, doctors did not know whether it would be safe or effective for people who had received organ or stem cell transplants, since these patients take medications that suppress the immune system to prevent rejection. This trial aimed to answer that important question.
Participants attended screening visits to confirm they met eligibility requirements, then received the study medication by intravenous infusion every three weeks. Stem cell transplant recipients received only the new medication, while kidney transplant recipients also received additional medications to prevent transplant rejection. Throughout the trial, participants had regular check-ups and blood tests to monitor how well the treatment worked and to watch for any side effects.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States